Antiviral solutions company Nanoveu (ASX:NVU) has reported a surge in international demand for its antiviral plastic film and phone screen protection covers.
The accelerating order book has combed for over A$250,000 in recent sales, driven by a number of distribution agreements.
Nanoveu reports that of its quarter of a million new sales, just over half of the proceeds already sit in the company’s bank account and the remainder of the outstanding balance anticipated on 30-day terms.
In another milestone for the Company, Nanoveu reports its maiden shipment of product into the market of Vietnam.
A $70,000 sale focussing on the Company’s antiviral phone screen protectors to Vietnam marks the first major sale for the company of the smartphone product.
Commenting on the sales activity Nanoveu Executive Chairman and CEO Alfred Chong said:
“Nanoveu is continuing to make strides to build up its order book and list of distributors. It is pleasing to see the various applications which the technology is being used for as well as the growing list of international partners.
“We are very excited to add another major destination such as Vietnam to our list of supplied countries and we now have sales in countries as diverse as the USA, Australia, UK, and Singapore.”
Other orders to feature within its expanding sales revenue include the deployment of its antiviral film at one of the largest shopping malls in Singapore.
Suntec City Mall, which is co-located with the major Suntec Convention Centre and hosts more than 360 retail outlets over 4 storeys, has applied the Nanoveu solution to 74 TV screen and touchscreen surfaces within the facility.
Nanoveu reports a number of additional sales discussions which are underway, with the Company looking to offer antiviral product for retrofitting on to self-check-in kiosks and security trays at airports, as well as for gaming and vending machines.
Pilot trials at hotel and restaurant chains are also underway.
Nanoveu’s antiviral technology has been independently demonstrated to be a highly effective agent for the eradication of viruses.
The technology has been proven to eliminate 99.99% of OC43, a viral strain affecting humans that is also a surrogate for COVID-19, in 30 minutes.
The antiviral protection has also been validated against other bacteria and viruses including e.Coli, Influenza A (subtype H3N2) and coronavirus MHV-A59.